These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 30357890)

  • 21. Discovery of 1-(3-aryl-4-chlorophenyl)-3-(p-aryl)urea derivatives against breast cancer by inhibiting PI3K/Akt/mTOR and Hedgehog signalings.
    Li W; Sun Q; Song L; Gao C; Liu F; Chen Y; Jiang Y
    Eur J Med Chem; 2017 Dec; 141():721-733. PubMed ID: 29107429
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dihydroartemisinin inhibits the mammalian target of rapamycin-mediated signaling pathways in tumor cells.
    Odaka Y; Xu B; Luo Y; Shen T; Shang C; Wu Y; Zhou H; Huang S
    Carcinogenesis; 2014 Jan; 35(1):192-200. PubMed ID: 23929438
    [TBL] [Abstract][Full Text] [Related]  

  • 23. mTOR inhibitors induce apoptosis in colon cancer cells via CHOP-dependent DR5 induction on 4E-BP1 dephosphorylation.
    He K; Zheng X; Li M; Zhang L; Yu J
    Oncogene; 2016 Jan; 35(2):148-57. PubMed ID: 25867072
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PDK1 Inhibitor GSK-470 Exhibits Potent Anticancer Activity in a Pheochromocytoma PC12 Cell Tumor Model via Akt/mTOR Pathway.
    Zhang X; Zhong S
    Anticancer Agents Med Chem; 2020; 20(7):828-833. PubMed ID: 32188393
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Selective CDK4/6 inhibition of novel 1,2,3-triazole tethered acridinedione derivatives induces G1/S cell cycle transition arrest via Rb phosphorylation blockade in breast cancer models.
    Praveenkumar E; Gurrapu N; Kolluri PK; Shivaraj ; Subhashini NJP; Dokala A
    Bioorg Chem; 2021 Nov; 116():105377. PubMed ID: 34670329
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synthesis and anti-proliferative activity of allogibberic acid derivatives containing 1,2,3-triazole pharmacophore.
    Wu MJ; Wu DM; Chen JB; Zhao JF; Gong L; Gong YX; Li Y; Yang XD; Zhang H
    Bioorg Med Chem Lett; 2018 Aug; 28(14):2543-2549. PubMed ID: 29884535
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Design and synthesis of novel 1,2,3-triazole-pyrimidine hybrids as potential anticancer agents.
    Ma LY; Pang LP; Wang B; Zhang M; Hu B; Xue DQ; Shao KP; Zhang BL; Liu Y; Zhang E; Liu HM
    Eur J Med Chem; 2014 Oct; 86():368-80. PubMed ID: 25180925
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A dual mTORC1 and mTORC2 inhibitor shows antitumor activity in esophageal squamous cell carcinoma cells and sensitizes them to cisplatin.
    Huang Y; Xi Q; Chen Y; Wang J; Peng P; Xia S; Yu S
    Anticancer Drugs; 2013 Oct; 24(9):889-98. PubMed ID: 23838676
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synthesis, anticancer activity and effects on cell cycle profile and apoptosis of novel thieno[2,3-d]pyrimidine and thieno[3,2-e] triazolo[4,3-c]pyrimidine derivatives.
    Kandeel MM; Refaat HM; Kassab AE; Shahin IG; Abdelghany TM
    Eur J Med Chem; 2015 Jan; 90():620-32. PubMed ID: 25499930
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A novel semisynthetic inhibitor of the FRB domain of mammalian target of rapamycin blocks proliferation and triggers apoptosis in chemoresistant prostate cancer cells.
    Morad SA; Schmid M; Büchele B; Siehl HU; El Gafaary M; Lunov O; Syrovets T; Simmet T
    Mol Pharmacol; 2013 Feb; 83(2):531-41. PubMed ID: 23208958
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hybrid inhibitors of phosphatidylinositol 3-kinase (PI3K) and the mammalian target of rapamycin (mTOR): design, synthesis, and superior antitumor activity of novel wortmannin-rapamycin conjugates.
    Ayral-Kaloustian S; Gu J; Lucas J; Cinque M; Gaydos C; Zask A; Chaudhary I; Wang J; Di L; Young M; Ruppen M; Mansour TS; Gibbons JJ; Yu K
    J Med Chem; 2010 Jan; 53(1):452-9. PubMed ID: 19928864
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Design and synthesis of novel quinoline/chalcone/1,2,4-triazole hybrids as potent antiproliferative agent targeting EGFR and BRAF
    Mohassab AM; Hassan HA; Abdelhamid D; Gouda AM; Youssif BGM; Tateishi H; Fujita M; Otsuka M; Abdel-Aziz M
    Bioorg Chem; 2021 Jan; 106():104510. PubMed ID: 33279248
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Discovery of novel 1,3,5-triazine derivatives as potent inhibitor of cervical cancer via dual inhibition of PI3K/mTOR.
    Hu J; Zhang Y; Tang N; Lu Y; Guo P; Huang Z
    Bioorg Med Chem; 2021 Feb; 32():115997. PubMed ID: 33440319
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Updates of mTOR inhibitors.
    Zhou H; Luo Y; Huang S
    Anticancer Agents Med Chem; 2010 Sep; 10(7):571-81. PubMed ID: 20812900
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An iridium (III) complex as potent anticancer agent induces apoptosis and autophagy in B16 cells through inhibition of the AKT/mTOR pathway.
    Tang B; Wan D; Wang YJ; Yi QY; Guo BH; Liu YJ
    Eur J Med Chem; 2018 Feb; 145():302-314. PubMed ID: 29331753
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Alterations of hypoxia-induced factor signaling pathway due to mammalian target of rapamycin (mTOR) suppression in ovarian clear cell adenocarcinoma: in vivo and in vitro explorations for clinical trial.
    Hirasawa T; Miyazawa M; Yasuda M; Shida M; Ikeda M; Kajiwara H; Matsui N; Fujita M; Muramatsu T; Mikami M
    Int J Gynecol Cancer; 2013 Sep; 23(7):1210-8. PubMed ID: 23899586
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synthesis and biological evaluation of 3-amino-1,2,4-triazole derivatives as potential anticancer compounds.
    Grytsai O; Valiashko O; Penco-Campillo M; Dufies M; Hagege A; Demange L; Martial S; Pagès G; Ronco C; Benhida R
    Bioorg Chem; 2020 Nov; 104():104271. PubMed ID: 32992279
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synthesis, inverse docking-assisted identification and in vitro biological characterization of Flavonol-based analogs of fisetin as c-Kit, CDK2 and mTOR inhibitors against melanoma and non-melanoma skin cancers.
    Roy T; Boateng ST; Banang-Mbeumi S; Singh PK; Basnet P; Chamcheu RN; Ladu F; Chauvin I; Spiegelman VS; Hill RA; Kousoulas KG; Nagalo BM; Walker AL; Fotie J; Murru S; Sechi M; Chamcheu JC
    Bioorg Chem; 2021 Feb; 107():104595. PubMed ID: 33450548
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dual mTOR/PI3K inhibitor NVP‑BEZ235 arrests colorectal cancer cell growth and displays differential inhibition of 4E‑BP1.
    Alqurashi N; Hashimi SM; Alowaidi F; Ivanovski S; Wei MQ
    Oncol Rep; 2018 Aug; 40(2):1083-1092. PubMed ID: 29845289
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PI3Kδ and mTOR dual inhibitors: Design, synthesis and anticancer evaluation of 3-substituted aminomethylquinoline analogues.
    Yevale D; Teraiya N; Lalwani T; Dalasaniya M; Kapadiya K; Ameta RK; Sangani CB; Duan YT
    Bioorg Chem; 2024 Jun; 147():107323. PubMed ID: 38583254
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.